公众号 / 文章复苏、休克与脓毒症创伤与烧伤

失血性休克辅助治疗:叙述性综述

Adjuvant therapies for management of hemorrhagic shock: a narrative review.
PubMed 文献 · Crit Care · 2025-03-29
一句话结论本综述提出六类可能辅助严重创伤失血性休克早期复苏的疗法:烟酸、噻唑烷二酮类、脯氨酰羟化酶结构域抑制剂、O-GlcNAc糖基化刺激、组蛋白去乙酰化酶抑制剂、腺苷-利多卡因-镁溶液。

严重出血仍是重大创伤患者的主要死因,多数失血性休克死亡发生迅速,甚至发生在到达医院之前。失血性休克时细胞氧供下降,尽管氧摄取增加仍发生无氧代谢,导致酸中毒、凝血病、细胞凋亡和器官功能障碍。本叙述性综述选取六种可能帮助细胞应对该情况的辅助治疗,包括烟酸、噻唑烷二酮类、脯氨酰羟化酶结构域抑制剂、O-GlcNAc糖基化刺激、组蛋白去乙酰化酶抑制剂和腺苷-利多卡因-镁溶液,逐一介绍其生物学机制及在失血性休克中的临床前和人体临床试验证据。结论指出,一些有前景的分子已用于人类其他适应证,为近期在失血性休克领域开展人体临床试验带来希望。

要点

  • 严重出血仍是重大创伤患者的主要死因,多数失血性休克死亡发生在初始创伤后迅速出现,且多数在患者到达医院前。
  • 失血性休克时细胞氧供下降,尽管氧摄取增加仍发生无氧代谢,导致酸中毒、凝血病、细胞凋亡和器官功能障碍。
  • 综述选取六种辅助治疗:烟酸、噻唑烷二酮类、脯氨酰羟化酶结构域抑制剂、O-GlcNAc糖基化刺激、组蛋白去乙酰化酶抑制剂、腺苷-利多卡因-镁溶液。
  • 上述六种治疗可能用于严重创伤患者初始复苏期间的辅助治疗,包括院外环境。
  • 结论认为一些有前景的分子已用于人类其他适应证,为近期在失血性休克领域开展人体临床试验带来希望。

适用人群与场景

  • 严重创伤失血性休克患者,处于初始复苏阶段,包括院外环境。

研究设计与关键结果

  • 本综述为叙述性综述,选取六种可能作为严重创伤患者初始复苏辅助治疗的方案:烟酸、噻唑烷二酮类、脯氨酰羟化酶结构域抑制剂、O-GlcNAc糖基化刺激、组蛋白去乙酰化酶抑制剂、腺苷-利多卡因-镁溶液;对每种治疗介绍其生物学机制及在失血性休克中的临床前数据和人体临床试验证据。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,一些有前景的分子已用于人类其他适应证,为近期在失血性休克领域开展人体临床试验带来希望。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Severe bleeding remains a leading cause of death in patients with major trauma, despite improvements in care during the acute phase, especially the application of damage control concepts. Death from hemorrhage occurs rapidly after the initial trauma, in most cases before the patient has had a chance to reach a hospital. Thus, the development of adjuvant drugs that would increase the survival of injured patients is necessary. Among the many avenues of research in this area, one is to improve cell survival during tissue hypoxia. During hemorrhagic shock, oxygen delivery to cells decreases and, despite increased oxygen extraction, anaerobic metabolism occurs, leading to acidosis, coagulopathy, apoptosis, and organ dysfunction.

METHODS: We selected six treatments that may help cells cope with this situation and could be used as adjuvant therapies during the initial resuscitation of severe trauma patients, including out-of-hospital settings: niacin, thiazolidinediones, prolyl hydroxylase domain inhibitors, O-GlcNAcylation stimulation, histone deacetylase inhibitors, and adenosine-lidocaine-magnesium solution. For each treatment, the biological mechanism involved and a systematic review of its interest in hemorrhagic shock (preclinical data and human clinical trials) are presented.

CONCLUSION: Promising molecules, some of which are already used in humans for other indications, give us hope for human clinical trials in the field of hemorrhagic shock in the near future.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Daniel Y, Dufour-Gaume F, Vergnaud A, et al. Adjuvant therapies for management of hemorrhagic shock: a narrative review. Crit Care. 2025. PMID: 40158128. doi:10.1186/s13054-025-05368-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。